Overview of KOMET-007: Ziftomenib Use in NPM-1m or KMT2A-r AML

With the Oncology Brothers, Uma Borate, MD, discusses how ziftomenib is showing promising results as a targeted therapy for NPM1-mutated and KMT2A-rearranged acute myeloid leukemia (AML) in the ongoing KOMET-007 trial, offering potential new treatment options for this challenging patient population.

Now Viewing

EP: 1.Overview of KOMET-007: Ziftomenib Use in NPM-1m or KMT2A-r AML

EP: 2.CPX-351 vs 7+3: AML-MR Mutations Drive the Benefit of CPX-351 Over 7+3

EP: 3.Venetoclax Combination: IDH1 Inhibitor Plus 7+3 Leads to Higher Remission and MRD

Recent Videos